MétaCan
Menu
Back to cohort
Record W2412571829 · doi:10.1177/135965350400900407

Salvage Therapy with Amprenavir, Lopinavir and Ritonavir 200 Mg/D or 400 Mg/D in HIV-Infected Patients in Virological Failure

2004· article· en· W2412571829 on OpenAlexaff
G Raguin, Geneviève Chêne, Laurence Morand‐Joubert, Anne-Marie Taburet, Clotilde Le Tiec, François Clavel, Pierre‐Marie Girard, Willy Rozenbaum, Lella Naït‐Ighil, TH Nguyen, Laurence Slama, PM Girard, Jean‐Michel Molina, D. Séréni, Nathalie Verdière, Caroline Lascoux‐Combes, Claire Pintado, Diane Ponscarme, F Prevoteau de Clary, Muriel Tourneur, M. Bentata, Loı̈c Guillevin, Odile Launay, Reza Mansouri, F. Rougès, M Kazatchkine, A. Aouba, Michel Azizi, JN Fiessinger, P Le Houssine, Didier Sicard, C Bernasconi, Dominique Salmon, Benjamin Silbermann, Cassuto Jp, C Ceppi, Dr Poiree, Mansouria Merad, Delfraissy Jf, Cécile Goujard, Yann Quertainmont, Christian Perronne, P. de Truchis, B Dupont, JL Bresson, I. Calatroni, François Raffi, JL Esnault, S Léautez

Bibliographic record

VenueAntiviral Therapy · 2004
Typearticle
Languageen
FieldMedicine
TopicHIV/AIDS drug development and treatment
Canadian institutionsHotel Dieu Hospital
Fundersnot available
KeywordsAmprenavirLopinavirRitonavirLopinavir/ritonavirMedicineVirologyReverse-transcriptase inhibitorViral loadInternal medicineGastroenterologyBiologyVirusAntiretroviral therapyProteaseHIV-1 proteaseEnzyme

Abstract

fetched live from OpenAlex

OBJECTIVES: To compare the antiviral efficacy of a salvage therapy combining lopinavir and amprenavir with 200 mg/d or 400 mg/d ritonavir, together with nucleoside reverse transcriptase inhibitors, over a 26-week period in HIV-infected patients in whom multiple antiretroviral regimens had failed. DESIGN: Phase IIb, randomized, open-label, multicentre trial. Patients were eligible if they had <500 CD4+ cells/mm3 and >4 log10 copies/ml HIV-RNA after treatment with at least two protease inhibitors (PIs) and one non-nucleoside reverse transcriptase inhibitor. RESULTS: At baseline (n=37), the median CD4+ cell count was 207/mm3 and the median plasma HIV-1 RNA level was 4.7 log10 copies/ml; the median number of PI mutations was seven and the median decrease in phenotypic susceptibility to lopinavir and amprenavir was 9.7 and 2.6, respectively. The mean number of antiretrovirals received prior to randomization was 7.7. The fall in the median HIV-1 RNA level at week 26 was -1.4 log10 copies/ml in the 200 mg/d ritonavir group and -2.5 log10 copies/ml in the 400 mg/d group (P=0.02). Viral load fell below 50 copies/ml in 32% and 61% of patients, respectively (P=0.07). After adjustment for the ritonavir dose, a smaller number of PI mutations was the only baseline characteristic associated with a better virological response at week 26. Amprenavir concentrations were significantly lower in presence of lopinavir. The lopinavir inhibitory quotient at week 6 correlated weakly with the change in the HIV-RNA level at week 26. CONCLUSION: Combination of amprenavir, lopinavir and 400 mg/d ritonavir shows significant virological efficacy without increased toxicity in HIV-infected patients in whom multiple antiretroviral regimens have failed.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.001
metaresearch head score (Gemma)0.001
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Non-randomized trial · Consensus signal: none
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.003
Threshold uncertainty score0.008

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0010.001
Meta-epidemiology (narrow)0.0010.000
Meta-epidemiology (broad)0.0030.001
Bibliometrics0.0000.000
Science and technology studies0.0000.000
Scholarly communication0.0010.001
Open science0.0010.000
Research integrity0.0010.001
Insufficient payload (model declined to judge)0.0020.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.015
GPT teacher head0.259
Teacher spread0.245 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designNon-randomized trial
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations24
Published2004
Admission routes1
Has abstractyes

Explore more

Same venueAntiviral TherapySame topicHIV/AIDS drug development and treatmentFrench-language works237,207